SillaJen, Inc. is dedicated to the advancement and commercialization of oncolytic immunotherapy products. Its primary therapeutic candidate, Pexa-Vec, is currently undergoing Phase II clinical evaluation as a potential treatment for late-stage liver cancer. The firm also has JX-970 in development, aimed at targeting tumor tissues, and the JX-900 series, which consists of modified vaccinia vaccines. Established in 2006, SillaJen is headquartered in Seoul, South Korea.